check these videos
…………
……….
High blood sugar leads to many long-term complications, including stroke, heart disease, poor circulation, kidney failure and diabetic retinopathy
Empagliflozin
The rising incidence of Type II diabetes has sparked a real need for more, and more effective, drug treatments for the condition. Growing levels of obesity tie in with this dramatic increase in diabetes, and while about 285 million people were estimated to have the Type II form in 1985, the number was just 30 million or so a mere 25 years earlier.1
– See more at:
http://www.manufacturingchemist.com/technical/article_page/Diabetes__empagliflozin/88178
A compound is being investigated as a Type II diabetes treatment by Lexicon Pharmaceuticals, although it is in an early stage of development
LX4211
A compound is being investigated as a Type II diabetes treatment by Lexicon Pharmaceuticals, although it is in an early stage of development.
LX4211 is not selective for just sodium glucose co-transporter-2, or SGLT-2 – it also inhibits SGLT-1.1 Inhibiting this second transporter, responsible for the absorption of glucose in the intestines, it also results in an increase in the release of glucagon-like peptide-1 (GLP-1), but might be combated by administering the dual inhibitor in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor to prevent it being activated.
– See more at:
http://www.manufacturingchemist.com/technical/article_page/Diabetes__LX4211/88179
